Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke - 18/08/11
, Barbara J. Nicklas, PhD a, b, Margaret D. Fallin, PhD c, Nathalie de Rekeneire, MD d, Stephen B. Kritchevsky, PhD a, Marco Pahor, MD a, Nicolas Rodondi, MD e, Rongling Li, PhD f, Joseph M. Zmuda, PhD g, Tamara B. Harris, MD dRésumé |
Background |
The 4G allele in the promoter region of the plasminogen activator inhibitor type 1 (PAI-1) gene is associated with higher plasma PAI-1 levels and activity, but its association with cardiovascular diseases is unclear. We investigated the association of polymorphisms and common haplotypes of the PAI-1 gene with plasma PAI-1 levels, as well as the risk of myocardial infarction and stroke.
Methods and Results |
This study is a prospective analysis of 2995 community-based participants (41% blacks and 51% women) aged 70 to 79 years old in the Health, Aging, and Body Composition Study. From 1997/1998 to 2001, 177 myocardial infarction events and 101 stroke events were identified. In addition to the 4G/5G polymorphism, 2 potential functional variants and other 4 haplotype-tagging variants were genotyped. In general linear models, the 4G allele was associated with higher PAI-1 levels after adjusting for age, sex, race, and site (26, 29, and 32 ng/mL for 5G/5G, 4G/5G, and 4G/4G, respectively; P for trend < .0001), but none of the other 6 polymorphisms was associated with PAI-1 levels. Haplotype analysis produced similar results. However, in Cox proportional hazard models, neither the polymorphisms nor the common haplotypes of the PAI-1 gene was associated with the risk of either myocardial infarction or stroke.
Conclusions |
The 4G allele is associated with higher PAI-1 levels, but this study does not support an association of the PAI gene polymorphisms with the risk of either myocardial infarction or stroke.
Le texte complet de cet article est disponible en PDF.Plan
| Support for this study was given by the Laboratory of Epidemiology, Demography and Biometry of the National Institute on Aging under National Institutes of Health's contract numbers N01-AG-6-2106, N01-AG-6-2102, and N01-AG-6-2103, and the Wake Forest University Claude D. Pepper Older Americans Independence Center (NIH P30-AG21332). In addition, Hologic Inc supported a validation study on body composition, but the investigators retained full independence in the conduct of this research. |
Vol 152 - N° 6
P. 1109-1115 - décembre 2006 Retour au numéro
Article précédent
- Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation
- Peter Leong-Sit, Lorne J. Gula, Pantelis Diamantouros, Andrew D. Krahn, Allan C. Skanes, Raymond Yee, George J. Klein
- Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes
- Amy R. Mank-Seymour, Jodi L. Richmond, Linda S. Wood, Jennifer M. Reynolds, Yu-Ti Fan, Gregory R. Warnes, Patrice M. Milos, John F. Thompson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?